Joseph Parnes, editor of Shortex, recommends buying Salt Lake City-based Myriad Genetics .
In the meantime, after Angelina Jolie's announcement, Myriad Genetics' stock rose to a three-year high.
In the case of BRCA1 and BRCA2, the patents are held by Myriad Genetics.
In June, Myriad Genetics found out its Flurizan had no effect whatsoever in a big trial.
That led to the debut of the BRCA test from Myriad Genetics in 1996.
In June, Myriad Genetics said its Flurizan anti-amyloid drug was totally ineffective in a final-stage trial.
Companies have seen a number of failures in amyloid-targeting drugs, including Myriad Genetics Inc.
This could pose a big threat down-the-road to companies like Myriad Genetics that sell expensive patented tests.
FORBES: Do-It-Yourself Gene Testing Threatens Myriad's Monopoly
Now Myriad Genetics is pushing a proprietary 46-gene test that predicts whether your prostate cancer will kill you.
Imagine if she had gone public urging women not to fall prey to Myriad Genetics marketing the BRCA1 genetic test.
FORBES: Will Angelina Jolie Help End Climate-Change Denial, And Help The Republican Party?
The Elan results come on the heels of the failure of an anti-amyloid drug from Myriad Genetics in a large trial.
Millennium Pharmaceuticals and Myriad Genetics, for instance, extract DNA samples from inbred societies in Finland and Costa Rica and from Utah's Mormons.
So far the company has sold licenses to two universities and eight U.S. companies, including Quest Diagnostics, Nanogen, Perlegen Sciences and Myriad Genetics.
"The market is saying Myriad Genetics is going to go into some type of decline, which I think is unlikely, " says Stephens analyst Scott Gleason.
Last month Myriad Genetics said it had discovered an obesity gene.
The U.S. Patent and Trademark Office has been awarding patents on human genes for almost 30 years, but opponents of Salt Lake City-based Myriad Genetics Inc.
In June, Myriad Genetics (nasdaq: MYGN - news - people ) said its Flurizan anti-amyloid drug was totally ineffective in a final-stage trial.
The U.S. Supreme Court agreed to hear, for a second time, a lawsuit challenging patents held by Myriad Genetics on human genes implicated in breast cancer.
FORBES: Supreme Court To Decide If Human Genes Can Be Patented In Myriad Case
The case involved Myriad Genetics, which holds the patent rights on two genes, BRCA1 and BRCA2, that are associated with increased risks for breast and ovarian cancer.
With the Supreme Court about to hear a landmark case on gene patents, Myriad Genetics, the company that owns the patents under scrutiny, is going on the offensive.
V. ( NASD: QGEN) is off about 2.6%, Illumina Inc ( NASD: ILMN) is down about 0.3%, and Myriad Genetics, Inc. ( NASD: MYGN) is lower by about 1.1%.
Myriad Genetics (MYGN), a leading developer of molecular diagnostic and therapeutic products, is predictably on track to expand its pipeline and broaden its markets in the U.S. and overseas.
Myriad Genetics subsequently licensed the patent rights from Utah, and has used them ever since to maintain its monopoly and prevent others from developing tests on the BRCA genes.
Salt Lake City-based Myriad Genetics mygn (nasdaq: mygn - news - people) has been finding genes in a Mormon population in its hometown since its inception in 1991.
To put that cost in perspective, Myriad Genetics, a Salt Lake City company that started out using the Mormon genealogies to find genes, charges thousands of dollars for its tests for breast cancer genes.
In research published in tomorrow's issue of Cell, scientists at Salt Lake City-based Myriad Genetics (nasdaq: MYGN - news - people ) and the University of Utah identify exactly which protein the virus appropriates in this microscopic hijacking.
The drug is also important to the marketing strategy of Salt Lake City-based Myriad Genetics mygn (nasdaq: mygn - news - people), a company that makes the only test for genes that can cause both breast and ovarian cancer.
More recently, Myriad Genetics threatened to sue researchers at the University of Pennsylvania and elsewhere for conducting testing on genes associated with breast cancer, leading the American Civil Liberties Union to sue the company for impeding research ( the ACLU lost).
FORBES: Biofuels Startup Gevo Must Win Patent War With BP, DuPont First
Among the largest underlying components of FBT, in trading today Biogen Idec Incorporated ( NASD: BIIB) is up about 6.8%, Myriad Genetics Incorporated ( NASD: MYGN) is up about 3.9%, and Vertex Pharmaceuticals Incorporated ( NASD: VRTX) is higher by about 1.8%.
Myriad Genetics later this year.
FORBES: What If They Treated Gene Patents Like Nautical Charts?
应用推荐